JNJ-64304500
JNJ-64304500 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
40.0%
2 of 5 finished
60.0%
3 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
A Study of JNJ-64304500 in Participants With Alopecia Areata
Clinical Trials (5)
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
A Study of JNJ-64304500 in Participants With Alopecia Areata
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5